A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

This is a single-arm, open-label, multicenter, non-indication seeking phase II trial to describe the efficacy and safety of patients with mantle cell lymphoma (MCL) receiving acalabrutinib in combination with R-CHOP for the front-line treatment of MCL in Spain. Acalabrutinib will be administered until disease progression if medically appropriate, along with R-CHOP based on institutional standards. After 6 cycles of acalabrutinib in combination with R-CHOP, subjects who tolerate treatment and not progressing, will then receive monotherapy acalabrutinib. In addition, subjects who achieve a resp

Trial Details

NCT ID
NCT07029737
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Mantle Cell Lymphoma Lymphoma
Interventions
  • Acalabrutinib + R-CHOP standard of care
  • Acalabrutinib combination with Rituximab
  • Acalabrutinib monotherapy
Locations (sample)
  • A Coruña, Spain|43.37135,-8.396
  • Alcorcón, Spain|40.34582,-3.82487
  • Badalona, Spain|41.45004,2.24741
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Adult men or women.
  • Pathologically confirmed MCL, with documentation of chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin D1 in association wi…
  • MCL requiring treatment and for which no prior systemic anticancer therapies have been received.
  • Unsuitable for autologous stem cell transplantation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mantle Cell Lymphoma Lymphoma Trials on Trialify →